Project Grant R01HL172845
Award Date
12/10/24
Completion Date
11/30/28
Dollars Obligated
$751K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $629,319 to Emory University to investigate methods for overcoming refractory cystic fibrosis (CF) defects. The research aims to identify cellular targets that can ameliorate disease by correcting basic defects resulting from premature termination codons (PTCs) in the CF transmembrane conductance regulator (CFTR) gene. Key research activities include...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,512 to The Leland Stanford Junior University to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy (DCM). The research utilizes induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) carrying DCM mutations to study the cellular and molecular mechanisms by which impaired proteostasis leads to cardiac dysfunction in...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $2,469,283 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to develop novel gene editing therapies for cystic fibrosis (CF). The project aims to use a homology-independent targeted integration (HITI) approach to permanently correct mutations in the CFTR gene and restore functional CFTR expression in airway epithelial cells,...
This federal Project Grant award of $730,494, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research to investigate the mechanisms linking the cystic fibrosis transmembrane conductance regulator (CFTR) protein to dysregulated barrier function, insulin receptor function, and glucose transport in the lungs of cystic fibrosis (CF) patients. The research aims to determine how the expression of mutant CFTR alters tight junction...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $107,948 to The Leland Stanford Junior University to engineer hematopoietic stem cells to generate therapeutic antibody-secreting B cells as a potential lifelong treatment for hypercholesterolemia. The project aims to use CRISPR/Cas9 genome editing to engineer hematopoietic stem and progenitor cells to produce B cells that secrete anti-PCSK9 antibodies,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,505,110 to The Leland Stanford Junior University to conduct research on human pulmonary neuroendocrine cells (PNECs) and their stem cells. The key objectives are to map the innervation and molecular subtypes of human PNECs, identify their functional subsets, and characterize the cellular and molecular features of PNEC stem cells and their niches. This...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $159,512 to The Leland Stanford Junior University to investigate strategies for mitigating cardiac fibrosis, a key contributor to dilated cardiomyopathy (DCM). The research aims to validate two candidate compounds identified in a prior drug screen, CGS15943 and AM404, using advanced techniques like 3D cardiac organoids and a mouse DCM...
This $705,405 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the role of adventitial fibroblasts, an understudied cell population, in the development and progression of atherosclerosis. The key objectives are to: Determine the mechanism by which targeted genetic ablation of adventitial fibroblasts decreases atherosclerotic plaque formation, despite these cells not directly contributing to the intimal...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling in mouse models and...